Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ZIOPHARM Oncology, Inc. (ZIOP)

0.8657   -0.008 (-0.88%) 12-31 19:00
Open: 0.89 Pre. Close: 0.8734
High: 0.97 Low: 0.8611
Volume: 2,127,546 Market Cap: 0(M)

Technical analysis

as of: 2022-04-01 4:25:12 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.23     One year: 1.44
Support: Support1: 0.77    Support2: 0.6
Resistance: Resistance1: 1.05    Resistance2: 1.23
Pivot: 0.77
Moving Average: MA(5): 0.86     MA(20): 0.77
MA(100): 1.03     MA(250): 1.83
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 71.4     %D(3): 71.4
RSI: RSI(14): 54.2
52-week: High: 3.73  Low: 0.6
Average Vol(K): 3-Month: 2,212 (K)  10-Days: 2,036 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ZIOP ] has closed below upper band by 22.6%. Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0

Company Description

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Headline News

Thu, 07 Apr 2022
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer - PR Newswire

Thu, 27 Jan 2022
Alaunos Therapeutics, Inc. (TCRT) Stock Price Today, Quote & News - Seeking Alpha

Wed, 26 Jan 2022
Ziopharm Rebrands As Alaunos Therapeutics - Yahoo Finance

Wed, 26 Jan 2022
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics - BioSpace

Tue, 11 Jan 2022
As ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) drops to US$212m market cap, insiders might rethink their US$639k stock purchase earlier this year - Nasdaq

Mon, 30 Aug 2021
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 216 (M)
% Held by Insiders 1.7244e+008 (%)
% Held by Institutions 9.9 (%)
Shares Short 32,730 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.566e+007
EPS Est Next Qtl -0.15
EPS Est This Year -0.57
EPS Est Next Year -0.61
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -22
Return on Assets (ttm) 103.5
Return on Equity (ttm) -39.4
Qtrly Rev. Growth 398000
Gross Profit (p.s.) 0
Sales Per Share -48.01
EBITDA (p.s.) -3.01143e+007
Qtrly Earnings Growth -0.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -63 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 4.73

Stock Dividends

Dividend 0
Forward Dividend 3.452e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.